Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- Simcere Pharmaceutical Group, a leading Chinese pharmaceutical and biotech firm, announced March 22 that its biopharmaceutical Endu (recombinant human endostatin injection) for non-small cell lung cancer (NSCLC) has completed Phase IV clinical trials and became the first drug to pass re-registration procedures outlined by China's State FDA
You may also be interested in...
Simcere Beefs Up Sales Force, Carves Out Provincial Sales Strategy To Drive Growth In China
SHANGHAI- U.S.-listed Simcere Pharmaceutical is expanding its sales force in China for future growth and recently received Chinese regulatory approval for palonosetron, a second-generation 5-HT3 antagonist for the prevention and control of acute chemotherapy-induced nausea and vomiting, the company announced during its most recent earnings call
Simcere Beefs Up Sales Force, Carves Out Provincial Sales Strategy To Drive Growth In China
SHANGHAI- U.S.-listed Simcere Pharmaceutical is expanding its sales force in China for future growth and recently received Chinese regulatory approval for palonosetron, a second-generation 5-HT3 antagonist for the prevention and control of acute chemotherapy-induced nausea and vomiting, the company announced during its most recent earnings call
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry